ATNX

Athenex Inc
0.2249
0.0338 (17.69%)
Upgrade to Real-Time
Afterhours (Closed)
0.2249
Volume 12,142,788
Bid Price 0.2212
Ask Price 0.225
News -
Day High 0.28

Low
0.1184

52 Week Range

High
1.20

Day Low 0.2011
Company Name Stock Ticker Symbol Market Type
Athenex Inc ATNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0338 17.69% 0.2249 19:59:41
Open Price Low Price High Price Close Price Prev Close
0.2028 0.2011 0.28 0.221 0.1911
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,829 12,142,788 $ 0.2413167 $ 2,930,258 - 0.1184 - 1.20
Last Trade Time Type Quantity Stock Price Currency
19:59:41 formt 100 $ 0.2249 USD

Period:

Draw Mode:

Athenex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 35.40M 157.41M 121.85M $ 120.18M $ -89.55M -1.92 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 742.63k 5.30%

more financials information »

Athenex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.190.280.180.18876811,164,0700.034918.37%
1 Month0.17910.280.17040.18381531,306,3110.045825.57%
3 Months0.2050.300.11840.16437914,223,2980.01999.71%
6 Months0.551.190.11840.28938492,994,477-0.3251-59.11%
1 Year1.001.200.11840.37221381,990,004-0.7751-77.51%
3 Years13.3515.670.11843.911,783,686-13.13-98.32%
5 Years14.3122.000.11845.611,278,537-14.09-98.43%

Athenex Description

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.